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ABSTRACT
Objective To assess the performance of novel contour
enhanced funnel plots and a regression based
adjustment method to detect and adjust for publication
biases.
Design Secondary analysis of a published systematic
literature review.
DatasourcesPlacebocontrolledtrialsof antidepressants
previously submitted to the US Food and Drug
Administration (FDA) and matching journal publications.
Methods Publication biases were identified using novel
contour enhanced funnel plots, a regression based
adjustment method, Egger’s test, and the trim and fill
method. Results were compared with a meta-analysis of
the gold standard data submitted to the FDA.
Results Severe asymmetry was observed in the contour
enhanced funnel plot that appeared to be heavily
influenced by the statistical significance of results,
suggesting publication biases as the cause of the
asymmetry. Applying the regression based adjustment
method to the journal data produced a similar pooled
effecttothatobservedbyameta-analysisoftheFDAdata.
Contrasting journal and FDA results suggested that, in
addition to other deviations from study protocol,
switching from an intention to treat analysis to a per
protocol one would contribute to the observed
discrepancies between the journal and FDA results.
Conclusion Novel contour enhanced funnel plots and a
regression based adjustment method worked
convincingly and might have an important part to play in
combating publication biases.
INTRODUCTION
In 2008 Turner et al published a study in the New Eng-
land Journal of Medicine showing that the scientific jour-
nal literature on antidepressants was biased towards
“favourable” results.
1 The authors compared the
results in journal based reports of trials with data on
the corresponding trials submitted to the US Food
and Drug Administration (FDA) when applying for
licensing. The discrepancies observed in the journal
basedreportswereduetopublicationbiases.Although
the term publication bias has been used historically to
refer to the suppression of whole studies based on (the
lack of) statistical significance or “interest level,” a
range of mechanisms can distort the published litera-
ture. These include, in addition to the suppression of
whole studies, selective reporting of outcomes or sub-
groups; data “massaging,” such as the selective exclu-
sionofpatientsfromtheanalysis;andbiasesregarding
timelines.
2 A good umbrella term for all these is disse-
mination biases
34; in keeping with common usage we
refer to them as publication biases. If such biases are
present, any decision making based on the literature
could be misleading,
56 not least through obtaining
inflated clinical effects from meta-analysis.
7
The FDA dataset is assumed to be an unbiased (but
not the complete) body of evidence in the specialty of
antidepressantsandsoisregardedagoldstandarddata
source owing to the legal requirements of submitting
evidenceinitsentiretytotheFDAanditscarefulmon-
itoring for deviations from protocol.
8-10 A gold stan-
dard dataset will not, however, be available in most
contexts. In the absence of a gold standard, meta-ana-
lysts have had to rely on analytical methods to both
detect and adjust for publication biases. This has been
an active area of methodology development over the
pastdecades,withmuchwrittenonapproachestodeal
with publication biases in a meta-analysis context.
2
These include graphical diagnostic approaches and
formalstatisticalteststodetectthepresenceofpublica-
tion bias, and statistical approaches to modify effect
sizes to adjust a meta-analysis estimate when the pre-
sence of publication bias is suspected.
2 While the per-
formance of many of these methods has been
evaluated using simulation studies, concerns remain
as to whether the simulations reflect real life situations
and therefore whether their perceived performance is
representativeofwhatwouldhappenif theywereused
in practice. Understandably this has led to caution in
theuseofthemethods,particularlyforthosethatadjust
effectsizesforpublicationbiases
6;butultimatelythisis
what is required for rational decision making if publi-
cation biases exist.
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methods for identifying and adjusting for publication
biases—both of which have been described only
recently.Specifically,we considera funnelplot (ascat-
ter plot of effect size versus associated standard error)
enhancedbycontoursseparatingareasofstatisticalsig-
nificancefromnon-significance.
11Thesecontourshelp
distinguish publication biases from other factors that
lead to asymmetry in the funnel plot. The method
used to adjust a meta-analysis for publication bias is
based on a regression line fitted to the funnel plot.
12
The adjusted effect size is obtained by extrapolating
the regression line to predict the effect size that would
be seen in a hypothetical study of infinite size—that is,
which has an effect size with zero associated standard
error. For comparison and completeness we consider
established methods to deal with publication bias.
These are the regression based Egger’s test for funnel
asymmetry,
13 and the trim and fill method,
14 which
adjusts a meta-analysis for publication bias by imput-
ing studies to rectify any asymmetryin the funnelplot.
The dataset from Turner et al provides a unique
opportunity to evaluate the performance of these ana-
lyticalmethodsagainstagoldstandard.Wepresentthe
resultsofapplyingthediagnosticandadjustmentmeth-
ods to the journal published results and compare the
findings with those obtained through (gold standard)
analysis of the data submitted to the FDA.
METHODS
A full description of the dataset, how it was obtained,
and the references to the trials associated with it have
been published previously.
1 Briefly, Turner et al iden-
tifiedthecohortofallphaseIIandphaseIIIshortterm
double blind placebo controlled trials used for the
licensing of antidepressant drugs between 1987 and
2004 by the FDA. Seventy four trials registered with
the FDA and involving 12 drugs and 12564 patients
were identified. To compare drug efficacy reported by
thepublishedliteraturewiththatoftheFDAgoldstan-
dard, Turner et al collected data on the primary out-
come from both sources. Once the primary outcome
data were extracted from the FDA trial registry, they
searched the published scientific literature for publica-
tionsmatchingthesametrials.Whenamatchwasiden-
tified, they extracted data on the article’s apparent
primary efficacy outcome. Because studies reported
their outcomes on different scales, they expressed all
effect sizes as standardised mean differences using
Hedges’ g scores (accompanied by corresponding
variances).
15 Among the 74 studies registered with the
FDA,23(31%),accountingfor3449participants,were
not published. Overall, larger effects were derived
from the journal data than from the FDA data.
Among the 38 studies with results viewed by the
FDA as statistically significant, only one was unpub-
lished. Conversely, inconclusive studies were, with
three exceptions, either not published (22 studies) or
published in conflict with the FDA findings (11 stu-
dies). Moreover, 94% of published studies reported a
positive significant result for their primary outcome,
compared with 51% according to the FDA. Data for
the analysis were extracted from the previous paper
(table C in the appendix),
1 in which two studies were
combined, making a total of 73 studies in our assess-
ment.
Analysis
We applied two novel methods to the journal dataset:
thecontourenhancedfunnelplot
1116todetectpublica-
tion biases, and a regression based adjustment
method
12 to adjust for them. For completeness and
comparison we also applied to the dataset the most
established and commonly used methods to deal with
publication biases—namely, Egger’s regression test
13
for detecting bias, and the trim and fill adjustment
method (fixed effects linear estimator).
1417-19 The trim
and fill method is an iterative non-parametric techni-
que that uses rank based data augmentation to adjust
forpublicationbiasbyimputingstudiesestimatedtobe
missing from the dataset. We use fixed effect models
for the primary analysis in this paper; we also reana-
lysed the data using random effects models as a sensi-
tivity analysis. Stata v.9.2 was used for all the analyses.
Contour enhanced funnel plots
In its simplest form a funnel plot is a scatter plot of
study effect sizes (x axis) against their estimated stan-
dard errors (y axis).
20 When no bias is present such a
plotshouldbesymmetrical,withincreasingvariability
in effect sizes beingobserved in the less precise studies
towards the bottom of the plot, producing a funnel
shape. Asymmetry in this plot may indicate that pub-
licationbiasesarepresentthroughthelackofobserved
data points in a region of the plot.
20 Asymmetry alone
does not necessarily imply publication biases exist,
however, since alternative explanations for the asym-
metry may be present.
21 For example, confounding
factors (that is, any unmeasured variable associated
with both study precision and effect size) may distort
the appearance of the plot. It has been observed that
certain aspects of trial quality may influence the esti-
mates of effect size,
22-25 and empirical evidence sug-
gests that small studies are, on average, of lower
quality and this could induce asymmetry on a funnel
plot.
26Mechanismssuchasthisleadtowhathavebeen
termedsmallstudyeffects,
2126-28andtheirpresencewill
also make funnel plots asymmetrical.
With a view to disentangling genuine publication
biasesfromothercausesoffunnelasymmetry,the fun-
nel plot can be enhanced by including contours that
partitionitintoareasofstatisticalsignificanceandnon-
significance
1116basedonthestandardWaldtest,mark-
ingtraditionallyperceivedmilestonesofsignificance—
for example, the 1%, 5%, and 10% levels.
29 In this way
thelevelofstatisticalsignificanceofeverystudy’seffect
estimate is identified. Since there is evidence that pub-
lication biases are related to these milestones,
3031 this
can aid interpretation of the funnel plot—that is, if stu-
dies seem to be missing in areas of statistical non-sig-
nificance,thenthisaddscredencetothenotionthatthe
asymmetry is due to publication biases. In such cases
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the absence of being able to obtain gold standard data
unaffectedbypublicationbiases,suchasdatafromreg-
ulatory authorities like the FDA). Conversely, if the
parts of the funnel where studies are perceived to be
missing are found in areas of higher statistical signifi-
cance, the cause of asymmetry is more likely to be due
to factors other than publication biases.
Regression based adjustment
The regression based adjustment method fits a regres-
sion line of best fit to the data presented on a funnel
plot.
32Anadjustedpooledestimateofeffectisobtained
by predicting, from the regression line, the pooled
effect size for an ideal study of infinite size (hence
with zero standard error), which would be located at
the top of a funnel plot; since it is hypothesised that
there would be no bias in studies of that size. This
idea has been discussed in the literature
33-35 (and addi-
tionally, such metaregressions are commonly used to
test for the presence of publication bias),
13 but only
recently has the notion been formally evaluated.
12 In
that evaluation the performance of several different
regression models was considered over an extensive
range of meta-analytical and publication bias scenar-
ios. The best models were shown to consistently out-
perform the established trim and fill method. One of
these, the quadratic version of the original Egger’s
regression test,
13 is implemented here. This assumes a
linear trend between the effect size and its variance
(rather than its standard error, as assumed in the origi-
nalEgger’stest).Othermodelsconsideredinthesimu-
lation study were designed for binary outcomes
exclusively and are not considered here.
RESULTS
Figure 1A displays a contour enhanced funnel plot of
thestudiessubmittedtotheFDA,withthecorrespond-
ing fixed effect meta-analysis pooled estimate provid-
ing a weighted average of effect sizes across trials (g
score 0.31, 95% confidence interval 0.27 to 0.35).
This funnel plot is reasonably symmetrical (Egger’s
test P=0.10), which is consistent with the hypothesis
thattheFDAisanunbiasedandappropriategoldstan-
dard data source.
The contour enhanced funnel plot for the journal
data (fig 1B) is different and highly asymmetrical
(Egger’s test P<0.001). A meta-analysis of these data
results in a higher average effect size (g score 0.41,
0.37 to 0.45). Most of the study estimates now lie
above (but many close to) the right contour line, indi-
cating a statistically significant benefit at the 5% level,
with few studies located below this 5% contour line—
that is, not reaching significance at the 5% level. Cru-
cially, the area where studies seem to be “missing” is
containedwithintheareawherenon-significantstudies
wouldbelocated;insidethetriangledefinedbyP=0.10
contour boundaries. This adds further credence to the
hypothesis that the observed asymmetry is caused by
publication biases. Hence, even without the availabil-
ity of the corresponding funnel plot for the FDA data
(fig 1A), a contour enhanced funnel plot has convin-
cinglyidentifiedpublicationbiasesasamajorproblem
for the journal data.
For the journal dataset, the trim and fill method
imputedatotalof18“missing”studies(allintheregion
of non-statistical significance indicated by squares in
figure 1C). This agrees reasonably well with the truth,
as 23 studies identified through the FDA registry were
not identified in the journal literature. The application
of the trim and fill method reduced the average effect
size to 0.35 (95% confidence interval 0.31 to 0.39),
which is about halfway between the FDA and journal
estimates (all three estimates are presented in figure
1C).
The fitted line corresponding to the regression based
adjustment method is plotted in figure 1D (orange
dashedline). The adjustedestimate isobtainedbyextra-
polating the line to where the standard error is 0 (at the
top of figure 1D). This produces an adjusted average
effect size of 0.29 (95% confidence interval 0.23 to
0.35), which is close to the estimate produced by the
meta-analysis of the FDA data (0.31, 0.27 to 0.35).
The situation is complicated by the fact that among
the FDA non-significant studiesthat were publishedin
medical journals, most were published as if they were
significant. This is investigated in figure 2A by linking
the effect sizes from each study where estimates were
available from bothdata sources(69% (n=50) of all the
trials), using arrows indicating the magnitude and
directionofchangebetweenFDAandpublishedeffect
sizes.TheeffectsizedifferedbetweenFDAandjournal
analyses in 62% (n=31) of the 50 trials by at least a g
score of 0.01. Of these, the journal published effects
were larger in 77% (n=24) of the studies (arrow point-
ingtoright).Asexpected,ameta-analysisofthesedata
produces a higher average effect size for the journal
data (g score=0.41, 95% confidence interval 0.37 to
0.45) compared with the matched FDA data (0.37,
0.33 to 0.41). About eight studies in figure 2 achieve
statistical significance at the 5% level when published
in medicaljournals,contradicting theirnon-significant
FDA submission, whereas no journal publication
revokes statistical significance previously reported to
the FDA. This suggests that reporting biases within
published studies are directed towards the realisation
of statistical significance. Similarly, 96% (n=21) of the
22 unpublished studies (in journals) were non-signifi-
cant when submitted to the FDA (fig 2B); which again
supports the hypothesis of the presence of publication
biases.Thefixedeffectmeta-analysisestimateforthese
22 unpublished studies (0.15, 95% confidence interval
0.08 to 0.22) was far lower than the one for published
studies (0.41, 0.37 to 0.45; fig 2B), adding further sup-
port that serious publication biases are present in the
journal data.
Areanalysisofthedatausingrandomeffectsmodels
produced similar results to the fixed effect (proportion
of total variability explained by heterogeneity (I
2) was
16% for the FDA data and 0% for the journal data).
36
Details are available on request from the first author.
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The application of two novel approaches to identify
and adjust for publication biases in a dataset derived
fromajournalpublication,whereagoldstandarddata-
setexists,producedencouragingresults.Firstly,detec-
tion of publication biases was convincing using a
contour enhanced funnel plot. Secondly, the regres-
sionbasedmethodproducedacorrectedaverageeffect
size, which was close to that obtained from the FDA
dataset (and closer than that obtained by the trim and
fill method).
This assessment does, however, have limitations.
Firstly, the findings relate to a single dataset and thus
are not necessarily generalisable to other examples.
Specifically, all the trials were sponsored by the phar-
maceutical industry and we make the assumption that
the FDA data are completely unbiased. Furthermore,
themethodsunderevaluationweredesignedprimarily
fortheassessmentofefficacyoutcomesandtheymight
not be appropriate for safety outcomes—for example,
theremaybe incentivesto suppressstatistically signifi-
cant safety outcomes (rather than non-significant
ones). This is an area that requires more research.
Debate is ongoing about the usefulness of funnel
plots and related tests for the identification of publica-
tion biases. Although their use is widely advocated
237
some question their validity,
2738-41 including in this
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Fig 1 | Contour enhanced funnel plots (95% CI at top). (A) Studies
submitted to Food and Drug Administration (FDA). (B) Studies
published in journals. (C) Implementation of trim and fill method
on journal data. (D) Implementation of regression adjustment
model on journal data (adjusted effect at top where SE is 0)
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Fig 2 | Contour enhanced funnel plots displaying discrepancy
between Food and Drug Administration (FDA) data and journal
data. (A) Arrows joining effect results from same studies when
both were available from FDA and journals. (B) Estimates of
effect only available from FDA (not journal published studies)
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42 We think the analysis presented here pro-
vides strong evidence that they do have a useful role.
Recentlytherehasbeenalotofresearchintorefining
tests for funnel plot asymmetry,
132643-45 and while we
support the formalisation of such an assessment, none
of the tests (nor trim and fill or the regression adjust-
ment method) considers the statistical significance of
the available study estimates. For this reason we think
the consideration of the contours on the funnel plot to
be an essential component of distinguishing publica-
tionbiasesfromothercausesoffunnelplotasymmetry.
We make no claim that the contours can distinguish
between the different mechanisms for publication
bias—forexample,whetheritismissingwholestudies,
selectivelyreportedoutcomes,or“massaged”datathat
have led to the distorted funnel plot. (Becausewe have
theFDAdata,wedogoontodisentanglethis(fig2)but
generallythiswillnotbepossible.)Butwedonotthink
this is an important limitation because all these biases
have the same effect in a meta-analysis—that is, they
are all assumed to be related to statistical significance
and they all result in an exaggeration of the pooled
effect. There is empirical evidence to support this
notion for the effect of reporting biases within pub-
lishedclinicaltrialsingeneral
46-48andfortrialsonanti-
depressants in particular.
14950 Potential mechanisms
that are known to induce this include: (a) selectivity
in which outcomes are reportedor labelled as primary
in journal publications; (b) post hoc searches for statis-
tical significance using numerous hypothesis tests—
that is, data dredging or fishing; and (c) selectivity in
the analysis methods applied to the data for journal
publication. Regarding the last point, the FDA makes
its recommendations based on the intention to treat
principle,
5152 whereas only half the journal publica-
tions are analysed and reported using this
approach.
53-56 The usual alternative—the per protocol
approach to analysis—excludes dropouts and non-
adherents (or patients with protocol deviations in gen-
eral)andaimstoestimatedrugefficacy,whichwilltend
to inflate effect sizes compared with the intention to
treat approach, which estimates effectiveness.
57-60 An
estimate from a per protocol analysis will generally
have less precision than for the associated intention to
treat analyses owing to the removal of patients with
protocol deviations,
6162 which would result in a shift
downwards along the y axis of a funnel plot. This is
consistent with what is observed in figure 2A, where
most arrows are in a downward (as well as right mov-
ing) direction. How much such a mechanism com-
monly contributes to funnel plot asymmetry would
be worthy of further investigation.
Fewmethodsforspecificallyaddressingoutcome
6364
and subgroup reporting biases
65 exist, and further
development of analytical methods to specifically
tackle aspects of reporting biases within studies is
encouraged. Nevertheless, it is reassuring that the
methods used in this article to address publication
and related biases generally seem to work well in the
presenceofmultipletypesofpublicationbiases.Weno
longer advocate the use of the trim and fill method
because of problems identified through simulation
studies.
124066 The regression adjustment method,
whichis easytocarry out,
67 consistently outperformed
the trim and fill method in an extensive simulation
study
12 (as well as within this particular dataset).
Weconsidertechnicalissuesrelatingtheinfluenceof
choice of outcome metric on the robustness of the
results, and analyses methods used within the assess-
ments. Firstly, the Hedges’ g score outcome metric
was used throughout the analysis. This includes a cor-
rection for small sample size. An alternative metric,
without the correction, is the Cohen’s d score, which
could also have been used. However this would have
negligible influence on the funnel plots presented here
sincethecorrectionisstillmodestevenforthesmallest
trials (n=25). An additional consideration is that the
contours on the funnels are constructed assuming nor-
mality of the effect size since they are based on the
Wald test. We acknowledge that this may not be
exactly the statistical test used in the original analyses
forsomeofthetrials.Forexample,fortrialswithsmall
sample sizes, a t test may have been used. However, as
theWaldandtteststatisticsconvergeasthesamplesize
increases, this is only going to affect the assessment of
the most imprecise trials at the bottom of the funnel,
and all our findings are clearly robust to this.
The73randomisedcontrolledtrialsconsideredhere
correspond to 12 different antidepressants. Despite
this, there was little statistical heterogeneity in both
datasets and so we carried out fixed effect analyses for
simplicity(andfindingsareconsistentifrandomeffects
areused).Thereisaneverpresenttensioninmeta-ana-
lysis between “lumping and splitting” studies, and an
argument could be made for allowing for specific dif-
ferences in drugtreatment by stratifyingthem and car-
ryingout 12 separateanalyses.Challengeswould arise
ifattemptingtodetectandadjustforpublicationbiases
in each of the analyses independently owing to the dif-
ficulty of interpreting funnel plots with small numbers
of studies and the limited power of statistical
methods.
26 We agree with the suggestions of Shang et
al,
68 in their assessment of biases in the homoeopathy
trialliterature(whichhassomecommonalitieswiththe
analysis presented here), that it is advantageous to
“borrow strength” from a large number of trials and
provide empirical information to assist reviewers and
readers in the interpretation of findings from small
meta-analyses that focus on a specific intervention.
Furthermore, investigations of extensions of the exist-
ing statistical methods that would formalise such ideas
for borrowing strength to produce stratum specific
tests and estimates of bias are under way.
Giventheapparentbiasesinthejournalbasedlitera-
ture for these placebo controlled trials on anti-
depressants, we are concerned about the validity of
the findings of a recent high profile network meta-
analysis
69 of non-placebo controlled trials on anti-
depressants as no assessment of potential publication
biases seemed to be carried out.
70
Undoubtedly the best solution to publication biases
is to prevent them from occurring in the first place.
2
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trial registry database, is one way of achieving this.
However, this is still a long way off from becoming a
reality for many analyses. Hence we often have to rely
onanalyticalmethodstodealwiththeproblem,andwe
believe that the contour enhanced funnel plot and the
regression based adjustment method provide impor-
tant developments in thetoolkit tocombatpublication
biases.
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